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Abstract: Bronchoscopy in the new millennium spells an exciting
time for the pulmonologist, which likens to Alice peering through
the looking glass into a wonderland of miniaturized probes, optics,
and technology that are advancing at a maddening pace. Although
scientists continue to push the envelope using nanotechnology that
may facilitate further miniaturization of probes to allow imaging at
the cellular or molecular level, it is opportune to evaluate the
strengths and weaknesses of available technologies and broncho-
scopic techniques for the diagnosis and staging of lung cancer, in its
early detection and palliation. We appraise current technologies and
what they hold for the future.
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Bronchoscopy dates back to the late 18th century whererigid illuminating tubes were used to examine the tra-
cheobronchial tree.1 Subsequently, with the introduction of
the fiberoptic bronchoscope by Ikeda et al.,2 bronchoscopy
has revolutionized the practice of pulmonary medicine. In
lung cancer, because of advances in real-time imaging and
catheter-based techniques, bronchoscopy not only remains
pivotal in diagnosis and staging but also allows therapeutic
intervention for airway restoration in patients with central
airway obstruction and treatment of early detected central
airway cancers. For peripheral lung nodules that are beyond
the visibility of the bronchoscope, computed tomography
(CT) guided, navigational methods, and endobronchial ultra-
sonography (EBUS) facilitate accurate targeting. Because
bronchoscopy allows access to the lung, it is also a tool that
enables researchers to better understand lung carcinogenesis,
discover biomarkers for early detection and prognostication,
and assess tumor response to targeted therapy by in vivo
microdynamic imaging.3–5
DIAGNOSIS
Conventional bronchial washing, brushing, and endobron-
chial and transbronchial biopsy have variable yields depending
on tumor location and accessibility. For endobronchial tumor,
forceps biopsy gives the highest yield (74%) compared with
brushing (59%) and washing (48%). The yield is increased
further to 88% when these modalities are combined. For periph-
eral lung lesions, transbronchial brush under fluoroscopy gives
the highest yield (52%) followed by transbronchial biopsy
(46%) and bronchial washing (43%). When bronchial washing,
fluoroscopic-guided transbronchial biopsy, and brush are com-
bined, they improve the yield to 69%.6 Addition of needle
aspiration for endobronchial, submucosal, peripheral pul-
monary lesion, or peribronchial lymph node has been
demonstrated to enhance diagnostic yield and is cost ef-
fective by obviating further need of invasive interventions
and unnecessary open-close thoracotomies.7,8
Targeting a solitary pulmonary nodule (SPN) detected
on CT scan presents a challenge because sensitivity of bron-
choscopy for detecting malignancy in SPN is dependent on
size of the nodule, its proximity to the bronchial tree, pres-
ence of CT bronchus sign (Figure 1), and prevalence of
cancer in the population of interest.9 For SPN measuring
more than 2.5 cm, the yield from fluoroscopic-guided trans-
bronchial biopsy is 62%, but when the SPN is less than 2.5
cm, the yield falls below 40%.10 A major advance is the
multidetector helical CT that allows data acquisition of the
entire thorax during a single breath hold and reformatting of
axial images into three-dimensional virtual bronchoscopy.11
This has led to more precise targeting of peripheral pulmo-
nary lesion for biopsy using either electromagnetic steering
probe or ultrathin bronchoscope.12–14
Electromagnetic navigation bronchoscopy (ENB, Su-
perDimension; Plymouth, MN) requires uploading of pa-
tient’s chest CT data and selection of reference anatomic
landmarks with virtual bronchoscopy before the procedure.
The patient is then placed on an electromagnetic board and a
sensor probe within a guide sheath (GS) inserted through the
working channel of bronchoscope is used to align preselected
reference points with patient’s own anatomic landmarks. The
probe is steered toward the target, and tissue sampling is
performed with forceps, needle, or curette guided by sheath
after withdrawal of the sensor probe. ENB is not real time
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because the uploaded CT data are acquired during patient’s
breath-hold, hence if confers a diagnostic accuracy of 69 to
74% and pneumothorax rate of 3%.13,14 Although positive
yields are not affected by location or size, median size of
nodules biopsied was more than 2 cm. Thus patient’s spon-
taneous respiration makes localization of small nodules less
than 2 cm in the lower lobes and close to the pleura
challenging.14,15 The cost of ENB system is US $150,000
and another US $1000 for each disposable catheter. Be-
cause of the exorbitant cost of ENB, similar modification
has been attempted using the ultrathin bronchoscope and
with good results.12
EBUS with radial probe is useful for sampling periph-
eral lesions. A prospective randomized study demonstrates
the superiority of EBUS-guided transbronchial biopsy (75%)
over fluoroscopic-guided transbronchial biopsy (31%) for
pulmonary nodules less than 3 cm. For pulmonary lesions
more than 3 cm, no difference in diagnostic capability be-
tween the procedures is observed.16 A technique that incor-
porates a GS through which the miniaturized EBUS radial
probe (UM-S20–20R, Olympus) is inserted, the GS covered
probe is introduced into the lesion through the working
channel of bronchoscope, the radial probe is then withdrawn,
and brush or biopsy forceps is guided by sheath to the lesion
for biopsy. Kurimoto et al.16 have reported that diagnostic
yield is higher when the radial probe is located within the
lesion (Figure 2) than when it is adjacent, efficacy of
EBUS-GS method does not seem to be affected by tumor size
and gives good yield even for lesions measuring 10 mm.
Similarly, EBUS-GS is also demonstrated to be useful for
fluoroscopically invisible SPN.17 A difficulty encountered is
in targeting small pulmonary lesions that are peripheral in
location and close to the pleura, which has prompted the
combined application of ENB and EBUS. In this prospective
study, patients were randomized to undergo ENB alone,
EBUS alone, or combined ENB-EBUS. In the combined
modality group, patients underwent navigation bronchoscopy
first with locatable sensor within catheter. When the target
was close, the sensor was removed and the EBUS probe was
inserted through the catheter. Forceps biopsies were per-
formed after EBUS confirmation that the catheter was close
to the target without fluoroscopy. Diagnostic yield from
combined ENB-EBUS (88%) was significantly higher than
ENB (59%) or EBUS (69%) alone, which was also observed
according to lesion size, lobar distribution, and malignant
pathology. The overall incidence of iatrogenic pneumothorax
was 6%, which was not different in the three groups. Better
yield achieved with combined modality was attributed to
overcoming deficiencies of one technology with the strength
of the other. ENB allows navigation of the EBUS probe to the
lesion, and EBUS facilitates real-time visualization and con-
firmation of target.18
STAGING
Another indication for transbronchial needle aspiration
(TBNA) is in the staging of lung cancer. Conventional TBNA
performed without real-time imaging has a variable yield of
20 to 74%. The puncture site for enlarged lymph nodes is first
determined by flipping over CT images for better correlation
with the endoscopic view. However, fear of inadvertent
puncture of neighboring vascular structures, damage to the
bronchoscope, technical difficulties with needle, and inade-
quate specimen for diagnosis, TBNA is not routinely prac-
ticed.19 Strategies have been proposed to improve the yield of
conventional TBNA, which include minimum passes per
lymph node station,20 direct smear technique for specimen
preparation,21 rapid onsite evaluation by cytopathologist,22
CT,23 and radial probe EBUS guided.24 With the advent of
virtual positron emission tomography/CT bronchoscopy, it is
possible that TBNA yield can be markedly increased by
targeting PET positive lymph nodes using electromagnetic
navigational technology25 and puncture sites determined by
the sensor probe.13
FIGURE 1. Computed tomography bronchus sign.
FIGURE 2. Endobronchial ultrasonography radial probe
within pulmonary nodule.
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Notably, another major advance in mediastinal staging
is the incorporation of curvilinear ultrasound to the tip of the
bronchoscope that produces sectorial imaging of the lymph
nodes. Coupled with color flow Doppler, EBUS allows safe
real-time aspiration of mediastinal lymph nodes by avoiding
surrounding vascular structures (Figure 3), and accuracy with
this technique is reported between 89% and 97%.26,27 In fact,
EBUS coupled with endoscopic ultrasound transesophageal
sampling of enlarged lymph nodes in the mediastinum
achieve a diagnosis in 94%, a figure comparable with medi-
astinoscopy but performed in a noninvasive manner. Both
techniques either singly or combined provide access to hilar,
pulmonary ligament, para-esophageal, and adrenal lymph
nodes that would otherwise be inaccessible with the medias-
tinoscope.28
PALLIATION OF CENTRAL AIRWAY
OBSTRUCTION DUE TO LUNG CANCER
Malignant central airway obstruction is a significant
cause of morbidity and mortality. Approximately 30% of
patients with lung cancer will present with airway obstruction
and 35% of this group will die of complications such as
hemoptysis, postobstuctive pneumonia, and asphyxia. Al-
though imminent asphyxiation could be temporarily relieved
by endotracheal intubation and mechanical ventilation, air-
way recanalization by bronchoscopic methods and stent
placement provide rapid relief of symptoms and allow time
for the institution of chemoradiotherapy for sustained pallia-
tion, improved quality of life, and prolonged survival.29
Selection of a therapeutic strategy depends on the type of
lesion (Figure 4), acuity of presentation, the patient’s general
health status, and physician’s expertise (Table 1).
Techniques for Immediate Airway
Recannalization
Laser Therapy
The most widely used laser for the treatment of endo-
bronchial tumors is the Neodymium-Yttrium-Aluminum-
Garnet (Nd-YAG). Because the Nd-YAG laser wavelength is
poorly absorbed by quartz material, it can be transmitted
through a flexible fiber. The flexibility of the fiber enables
distal airway lesions to be treated with either the rigid or
flexible bronchoscope, and the versatility of the laser allows
for tissue coagulation at low power and vaporization at high
power.
FIGURE 3. Real-time endobronchial ultrasonography trans-
bronchial needle aspiration of left paratracheal lymph nodule.
FIGURE 4. Three main types of
tracheal obstruction and
management.
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Nd-YAG laser can be used to restore airway patency
emergently or electively, and effectively debulk tumors by a
combination of coring out techniques, deep tissue coagula-
tion, and vaporization.30 Laser photoresection of a large
endobronchial tumor (Figure 5) is very effective not only for
symptom palliation such as cough, dyspnea, and hemoptysis
but also in achieving endoscopic, radiographic, spirometric,
and quality-of-life improvements.31,32 Timely recognition and
prompt intervention avoid mechanical ventilation for patients
in extremis and facilitate weaning and successful extubation
in those who are mechanically ventilated.33 Factors that
influence the outcome of laser therapy are listed in Table 1.
Endobronchial Electrosurgery and Argon Plasma
Coagulation
Endobronchial electrosurgery (EBES) is as effective as
the laser for tumor ablation and control of hemoptysis, but
EBES is cheaper and portable. Although the new diode lasers
are designed to be portable, they are still located in major
operating rooms and require special connection ports for
TABLE 1. Algorithm for the Management of Malignant Airway Obstruction
Malignant Central Airway Obstruction
Bronchoscopy & Staging (TNM)
Operable
Yes No No
Surgery       Symptomatic/>50% obstruction Asymptomatic/<50% obstruction
Therapeutic Bronchoscopy Radiation / Chemotherapy  
Desired Result
Emergent Elective
Endobronchial   Extrinsic        Mixed Endobronchial    Extrinsic Mixed
Obstruction       Compression  Lesion Obstruction Compression       Lesion
LPRa                 Stenta              LPRa LPRb  Brachytherapyb    LPRb
EBES EBES Cryotherapy Radiation therapy EBES
Cryotherapyc Stent EBES Chemotherapy         Stent
PDT
Brachytherapy
Radiation/ Chemotherapy
a Followed by chemotherapy +- radiation therapy
b Can be used singly or in combination
c in selected cases using special cryoprobes
LPR, laser photoresection; EBES, endobronchial electrosurgery; PDT, photodynamic therapy.
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application. EBES is considered an effective alternative to
laser and can be performed through rigid or flexible broncho-
scope with a grounded neutral plate attached to the patient. It
is contraindicated for patients with cardiac pacemaker. EBES
is a contact technique that is effective for tumor debulking by
first coagulating the base with a probe followed by mechan-
ical debulking with the bevel of the rigid bronchoscope.34
Alternatively, the polypoid tumor can be removed by cutting
through the stalk with a snare through the flexible broncho-
scope (Figure 6).
EBES can be set to “cut,” “coagulate,” or “blend” by
varying the amperage and voltage of electrical current. In a
study that compared the degree of tissue injury caused by cut,
coagulation, and blend modes, depth of tissue injury caused
by coagulation current was significantly greater compared
with blend and cut modes. Use of cutting current in the blend
mode is recommended, because it is not only suitable for
incision but also provides effective hemostasis with minimal
tissue injury.35
Argon plasma coagulation (APC) is an electrosurgical
modality in which equipment modifications allow electrical
current to be applied in a noncontact mode through ionized
argon gas, which acts as a conductor between electrode and
tissue. It provides homogenous conduction of electrons, and
also around corners making APC particularly useful for
superficial hemorrhagic tumors, difficult to access upper lobe
and superior basal lobar bronchial tumors36,37 and granulation
tissue around airway stents.38
FIGURE 5. Favorable endobronchial tumor for laser.
FIGURE 6. Polypoid endobronchial
tumor in left main bronchus re-
moved by electrosurgical snare.
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Techniques for Delayed Airway
Recannalization
Airway lesions that do not necessitate immediate res-
toration of airway patency can be treated with intraluminal
brachytherapy, cryotherapy, or photodynamic therapy (PDT).
Brachytherapy
Brachytherapy refers to the temporary placement of
encapsulated radioactive sources near or within an endobron-
chial or parabronchial malignancy to deliver local irradiation.
The radioactive source can be implanted directly into the
tumor, placed in the tumor bed after surgery, or through
bronchoscopy. Improvements in the afterloading technique
with iridium-192 enable bronchoscopic administration of
high dose-rate brachytherapy on an outpatient basis with
minimal hazard to healthcare personnel. The main advantage
of this method is it allows high-dose irradiation of the tumor
with rapid fall-off outside the treatment area. Brachytherapy
is curative for early central airway cancers, small endobron-
chial and peripherally located tumors and can also be used for
symptom palliation in patients who have received maximum
dose of external beam irradiation.39 However, it is contrain-
dicated in tumors that invade major arteries or structures
within the mediastinum, and complications include radiation
bronchitis in 10% and hemoptysis in 7% of patients.40,41
Cryotherapy
Cryotherapy involves repetitive rapid cooling and slow
thawing with a special probe that conducts liquid nitrogen or
nitrous oxide. This results in intracellular ice-crystal forma-
tion that causes cell death and tissue destruction. Generally,
three cycles of freezing and thawing are performed at each
location and each freezing period lasts 20 seconds. Cryother-
apy has been applied to treat malignant airway lesions,42,43
and an ideal lesion for cryotherapy is a small, polypoidal
tumor that is accessible to the probe with distal visibility of
bronchial segments and functional lung. Cryotherapy is per-
formed with the rigid or flexible cryoprobe and has been
shown to potentiate the immunogenic effects of chemoradia-
tion therapy.42,44
Although the action of cold on tissues causes delayed
vascular thrombosis and necrosis, some investigators have
used improved cryoprobes to remove large endobronchial
tumors obstructing the central airways in which the cryoprobe
tip is pushed into the protruding exophytic tumor, and freez-
ing starts for about 5 seconds. The cryoprobe is abruptly
removed together with tumor tissue frozen at the tip. The
procedure is repeated until the tumor mass has been removed
and the bronchus recannalized. Success in airway recanaliza-
tion is more than 90% without complications, and clean up
bronchoscopy is not required.45 The same investigators have
also reported that tissue specimens obtained with the cryo-
probe are larger and of superior quality compared with those
using the forceps.46
Photodynamic Therapy
PDT causes tissue necrosis through toxic oxygen radicals
produced by the combined effect of a tumor-localizing photo-
sensitizer dihematoporphyrin ether/ester (Photofrin, Axcan
Pharma Inc., Birmingham, AL) and photons of appropriate
wavelength (630 nm) delivered by an argon or diode laser.
Photofrin is administered intravenously at 2 mg/kg and is re-
tained preferentially by tumor, reticuloendothelial tissues, and
skin. The tumor is then exposed to laser light 40 to 50 hours
later, which initiates a chain reaction resulting in cell death by
superoxide and hydroxyl radicals, and tissue necrosis by vascu-
lar thrombosis from thromboxane A2 release. Cleanup bron-
choscopy is often necessary 2 to 4 days after the procedure. PDT
is indicated for nonemergent palliation of obstructing tumors,
treatment of synchronous and early lung cancers.47–49
Moghissi et al.49 showed that when PDT was used to
treat 100 patients with airway obstruction, airway patency
improved by 68% with corresponding increases in forced
vital capacity and forced expiratory volume in 1 second.
Median survival after PDT was also better compared with
other treatment modalities. Although complications of PDT
are few such as dyspnea from airway obstruction because of
tissue swelling, photosensitivity, and hemoptysis, its delayed
effect precludes its use in acutely dyspneic patients. Need for
regular cleanup bronchoscopy, avoidance of sunlight for 2 to
6 weeks depending on the photosensitizer and the relatively
high cost make PDT less attractive.47–49
TABLE 2. Factors that Influence Outcome of Nd-YAG LPR
Factors Favorable Unfavorable
Location Trachea, main bronchi Lobar, segmental
bronchi
Type of lesion Endobronchial Extrinsic
Appearance Polypoid, exophytic,
pedunculated
Submucosal
Extent of involvement Localized (one wall) Extensive (1 wall)
Length of lesion 4 cm 4 cm
Distal lumen Visible Not visible
Duration of collapse 4–6 wk 4–6 wk
Clinical status
Hemodynamics Stable Unsatble
Oxygen requirement 40% FiO2 40% FiO2
Coagulation profile Normal Abnormal
Pulmonary vascular supply Intact Compromised
Nd-YAG LPR, Neodymium-Yttrium-Aluminium-Garnet laser photoresection.
TABLE 3. Indications for Stent Placement
1 Airway obstruction from extrinsic bronchial compression or submucosal
disease
2 Obstruction from endobronchial tumor when patency is 50% after
bronchoscopic laser therapy
3 Aggressive endobronchial tumor growth and recurrence despite
repetitive laser treatments
4 Loss of cartilaginous support from tumor destruction
5 Sequential insertion of airway and esophageal stents for
tracheoesophageal fistulas
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EXTRINSIC AIRWAY COMPRESSION
Stents
Airway stent insertion is effective in maintaining air-
way patency from extrinsic airway compression due to tumor.
Available types include silicone tube, covered and uncovered
metallic, and hybrid stents. Table 2 describes the indications
for stent placement and Table 3 illustrates the differences
between silicone tube and metallic stents.
Silicone Tube Stents
These stents are advantageous because they can be
customized to conform to the airways (Figure 7). The silicone
Y stent can be used if the distal trachea, bifurcation, and
proximal bronchi are compressed or infiltrated by tumor.
Silicone stents can be easily repositioned and removed,
and is less expensive. However, they are associated with a
higher migration rate and require the rigid bronchoscope
for insertion.50,51
Metallic Stents
These stents can be placed with the flexible broncho-
scope under local anesthesia in an outpatient setting (Figure
8). They have greater airway cross-sectional diameters, con-
form better to tortuous airways, and allow for mucociliary
clearance and ventilation across a lobar bronchial orifice
(Table 4).52 Major disadvantages include obstructing granu-
loma, cracks from metal fatigue, and difficulty in removal or
repositioning after epithelialization has occurred.53 Because
tumors can grow through the gaps of uncovered metallic
FIGURE 7. Adenoidcystic carcinoma
of trachea with near total obstruction.
Laser photoresection of obstructing
tumor via rigid bronchoscopy and
silicone stent insertion.
FIGURE 8. Tracheoesophageal fis-
tula with covered Ultraflex stent
performed using flexible bronchos-
copy at outpatient setting.
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stents, covered ones with silicone membrane of appropriate
size and length should be used. If the airway becomes
occluded by tumor ingrowth or granulation tissue, laser should
be avoided, because covered metallic stents are flammable,
cryotherapy or APC used in conjunction with brachytherapy are
safe and effective alternatives.38,41,42 A new self-expanding niti-
nol Y stent has been described for treatment of central tumors
affecting the distal trachea, bifurcation, and proximal main
bronchi.
EARLY LUNG CANCER DETECTION AND
INTERVENTION
Five-year survival of lung cancer remains dismal at
16%54 and is conceivable that better outcome can be achieved
if lung cancer is diagnosed and treated early. Improved CT
imaging can detect peripheral tumors, those occurring in the
central airways that are radiographically invisible, they can
be diagnosed by sputum cytology and bronchoscopy.55 As
these preinvasive lesions show subtle changes such as red-
ness, thickening, and granular appearance, it is not surprising
that only 30% are detected by white light bronchoscopy.56
Moderate dysplasia has 11% risk, whereas severe dysplasia
and carcinoma in situ have 40 to 83% risk of progression to
invasive lung cancer.57 Localizing these preinvasive lesions
would allow local treatment or lung conservation strategy.
Autofluorescence Bronchoscopy
When bronchial surface is illuminated by light, light
can be absorbed, reflected, back scattered, or induce fluores-
cence. Reflectance imaging (e.g., white light bronchoscopy)
defines structural features of bronchial epithelium to discrim-
inate normal from abnormal, whereas autofluorescence (AF)
bronchoscopy depends on the concentration of fluorophores
in the bronchial tissue. Normal bronchial epithelium fluo-
resces in green when illuminated by blue light, because it
transforms through different grades of dysplasia, carcinoma
in situ to invasive cancer a progressive decline in green
fluorescence due to increased epithelial thickness and tumor
neovascularization occurs, making these abnormal areas ap-
pear red. The spectral differences between 500 and 700 nm
for normal, preneoplastic, and neoplastic tissues serve as
basis for the development of AF-reflectance imaging devices
such as OncoLIFE, D-light, SAFE 3000, and AFI. Numerous
studies have consistently demonstrated superiority of AF
during white-light bronchoscopy for the detection of prein-
vasive lesions and early lung cancer. However, AF has a high
false-positive rate when bronchitis or airway inflammation is
encountered.58–61
FIGURE 9. Color fluorescence
(red/green) ratio of carcinoma in
situ.
TABLE 4. Comparison of the Dumon Stent and the
Covered Ultraflex Stent
Characteristics
Dumon
Stent
Covered Utraflex
Stent
Mechanical considerations
High internal to external
diameter ratio
 
Resistant to recompression
when deployed
 
Radial force exerted uniformly
across stent
 
Absence of migration  
Flexible for use in tortuous
airways
 
Removable  
Dynamic expansion  
Can be customized  
Tissue-stent interaction
Biologically inert  
Devoid of granulation tissue  
Tumor ingrowth  
Ease of use
Can be deployed with FB  
Deployed under local
anesthesia with conscious
sedation
 
Radiopaque for position
evaluation
 
Can be easily repositioned  
Cost
Inexpensive  
, poor; , fair; , good; , best.
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Our recent evaluation of real-time simultaneous video-
and AF-imaging using SAFE 3000 demonstrated good sen-
sitivity (0.85) for the detection of preinvasive lesions with
improved specificity (0.94) for targeted biopsy, which led to
a marked decrease in procedural time.62 By calculating the
red to green ratio of the abnormal airway site, we have also
shown that a derived color fluorescence ratio of 0.54 or more
correlated with the histologic finding of moderate to high-
grade dysplasia and could serve as an objective guide to
biopsy (Figure 9).63
Narrow band imaging (NBI) technology that uses two
wavelengths of light namely blue light (390–440 nm) that is
absorbed by superficial capillaries and green light (530–550
nm) by blood vessels beneath the mucosa enhances visual-
ization of vascular patterns of the tracheobronchial tree.
Previous studies have demonstrated correlation between
bronchial vascular pattern and angiogenic squamous dyspla-
sia recognized as precursor of early cancer and a more
sensitive bronchoscopic imaging tool for the detection of
preneoplasia.64,65 In a recent report by Herth et al.,66 NBI was
found to be more specific than AF without compromising
sensitivity in the detection of airway preneoplastic lesions.
Bronchoscopic Treatment of Early Lung Cancer
Precise staging of early central airway cancer is ex-
tremely important for the selection of appropriate treatment.
Although surgery is still the preferred option, many patients
harboring these cancers have smoking-related comorbidities
that place them at high surgical risk. Moreover, 20 to 30% of
these early cancers are multifocal,67 highlighting the need for
lung preservation strategies, which propel bronchoscopic
techniques forward as attractive alternatives.
The criteria of early central airway cancers suitable for
bronchoscopic treatment must first be radiographically oc-
cult, without lymph node and distant metastasis. The squa-
mous cell cancer should measure less than 2 cm in greatest
dimension with visible distal margin and confined within the
cartilaginous layer of the tracheobronchial tree.55,68 Investi-
gators are suggesting multimodality approach that includes
the combined use of high resolution CT, positron emission
tomography, AF, and EBUS to accurately stage these early
cancers to aid selection of appropriate therapy.69–71
To date, PDT is the most established treatment for early
central airway cancers with 60% 5-year survival and more
than 90% cancer-specific survival.72 Complete response was
also achieved in 97% of patients with early cancers 1 cm2
treated with EBES.70 Other bronchoscopic techniques dem-
onstrating good tumor response include high dose rate-
brachytherapy (85%) and cryotherapy (97%).73,74
RESEARCH IN TUMOR MARKERS AND NEW
DIAGNOSTIC OPTICAL TECHNOLOGIES
Bronchoscopy offers researchers access into the lung and
biomarkers have been developed to prognosticate and identify
individuals at risk for lung cancer.75 Sensitive bronchoscopic
techniques such as AF and NBI allow early detection and
detailed characterization of microvascular patterns to advance
the understanding of angiogenesis and its role in early carcino-
genesis; Raman spectroscopy that measures biochemical com-
position and metabolic state of bronchial tissues facilitates dif-
ferentiation of preinvasive from benign lesions76; and confocal
microendoscopy that provides cellular images are novel imaging
methods to study lung carcinogenesis.77
Optical coherence tomography (OCT) detects backscat-
tered light instead of sound waves, and because light is
200,000 times faster than sound, low coherence interferom-
etry is required to integrate reflectance properties of tissue
scanned to produce high-resolution cross-sectional microim-
ages. For the airway, OCT can display structures of the
bronchial wall in great detail and potentially allows real-time
noninvasive histologic imaging without the actual perfor-
mance of biopsy (Figure 10). OCT and confocal microendos-
copy may be nonbiopsy tools to facilitate our understanding
of the evolution of preinvasive lesions and the effect of
chemopreventive intervention.78,79 Whether OCT and confo-
cal microendoscopy will be more precise for tumor assess-
ment require investigation.
FIGURE 10. Squamous cell carcinoma of trachea. Bronchoscopic images: (A) nodular tumor and (B) normal tracheal wall op-
tical coherence tomography (OCT) images: Tumor (A) infiltrating beyond the cartilage and (B) normal OCT.
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CONCLUSION
These are indeed exciting times for clinicians and
scientists interested in lung cancer detection and therapy.
Biomarkers, novel imaging tools, and techniques improve
cancer detection at the early stages and when combined with
precise staging allow institution of lung preservation strate-
gies. Research into tumor markers and receptors pursue an
era for targeted and cancer-specific therapies, which demon-
strate greater efficacy and with fewer adverse effects.80 Al-
though randomized clinical trials in diagnostic and therapeu-
tic bronchoscopy are few, use of appropriate technologies
depends on the skill of the bronchoscopists and availability of
equipment. In patients with advanced lung cancer for whom
palliation is required, opportune use of interventional bron-
choscopic techniques provide symptom relief, longer sur-
vival, and improved quality of life.
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